Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of HIPRA COVID-19 Vaccine in Healthy Adults
NCT05007509Phase 2Completed
- Sponsor
- HIPRA
- Start
- Aug 2021
- Primary completion
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PHH-1V in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by HIPRA. Primary endpoints: Solicited local and systemic reactogenicity adverse events at 7 days and Unsolicited local and systemic reactogenicity adverse events at 28 days. Started Aug 2021; status: completed.
02
Drugs
PHH-1V
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05007509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007509.